Nabila Ansari1, Michael J Solomon, Richard J Fisher, John Mackay, Bryan Burmeister, Stephen Ackland, Alexander Heriot, David Joseph, Sue-Anne McLachlan, Bev McClure, Samuel Y Ngan. 1. *Surgical Outcome Research Centre (SOuRCe, The Institute of Academic Surgery at Royal Prince Alfred Hospital, University of Sydney, Sydney, New South Wales, Australia †Peter MacCallum Cancer Centre, Centre for Biostatistics and Clinical Trials, Melbourne, Victoria, Australia ‡Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia §Princess Alexandra Hospital, The University of Queensland, Woolloongabba, Queensland, Australia ¶Department of Oncology, Calvary Mater Hospital, Newcastle, New South Wales, Australia ||Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia **Department of Oncology, St. Vincent's Hospital, Melbourne, Victoria, Australia ††Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia ‡‡Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Abstract
OBJECTIVE: To compare acute adverse events (AE) and postoperative complication rates in a randomized trial of short-course (SC) versus long-course (LC) preoperative radiotherapy. BACKGROUND: Evidence demonstrates that adding neoadjuvant radiotherapy to surgery offers better local control in the management of rectal cancer. With both SC and LC therapy there is a potential for acute treatment-related toxicity and increased patient morbidity. METHODS:Eligible patients had clinical-stage T3 rectal adenocarcinoma within 12 cm of the anal verge with no evidence of metastasis. SC consisted of pelvic radiotherapy 5 × 5 Gy in 1 week, early surgery and 6 courses of adjuvant chemotherapy. LC was 50.4 Gy administered in 28 fractions during 5.5 weeks, with infusion 5-fluorouracil, surgery in 4 to 6 weeks, and 4 courses of chemotherapy. RESULTS: All SC patients and 93% of LC patients received preoperative planned radiotherapy. There was no 30-day operative mortality. A statistically significant higher percentage of at least 1 AE occurred in the LC group (SC, 72.3%; LC, 99.4%; P < 0.001). There were significant differences in favor of SC for grade 3 AE: radiation dermatitis (0% vs 5.6%, P = 0.003), proctitis (0% vs 3.7% P = 0.016), nausea (0% vs 3.1%, P = 0.029), fatigue (0% vs 3.7%, P = 0.016) and grade 3/4 diarrhea rates (1.3% vs 14.2% P < 0.001). No statistically significant differences in surgical complication rates were seen (SC 53.2 vs 50.4% LC, p = 0.68), although permanent stoma (38.0% vs 29.8%, P = 0.13) and anastomotic breakdown (7.1% vs 3.5%, P = 0.26) rates favored LC with perineal wound complications (38.3% vs 50.0%, P = 0.26) in favor of SC. CONCLUSIONS:LC had significantly higher AEs compared with SC with no statistically significant differences in postoperative complications. There were clinical trends in permanent stoma rates and anastomotic leaks in favor of LC but with an increased perineal wound breakdown rate.
RCT Entities:
OBJECTIVE: To compare acute adverse events (AE) and postoperative complication rates in a randomized trial of short-course (SC) versus long-course (LC) preoperative radiotherapy. BACKGROUND: Evidence demonstrates that adding neoadjuvant radiotherapy to surgery offers better local control in the management of rectal cancer. With both SC and LC therapy there is a potential for acute treatment-related toxicity and increased patient morbidity. METHODS: Eligible patients had clinical-stage T3 rectal adenocarcinoma within 12 cm of the anal verge with no evidence of metastasis. SC consisted of pelvic radiotherapy 5 × 5 Gy in 1 week, early surgery and 6 courses of adjuvant chemotherapy. LC was 50.4 Gy administered in 28 fractions during 5.5 weeks, with infusion 5-fluorouracil, surgery in 4 to 6 weeks, and 4 courses of chemotherapy. RESULTS: All SC patients and 93% of LCpatients received preoperative planned radiotherapy. There was no 30-day operative mortality. A statistically significant higher percentage of at least 1 AE occurred in the LC group (SC, 72.3%; LC, 99.4%; P < 0.001). There were significant differences in favor of SC for grade 3 AE: radiation dermatitis (0% vs 5.6%, P = 0.003), proctitis (0% vs 3.7% P = 0.016), nausea (0% vs 3.1%, P = 0.029), fatigue (0% vs 3.7%, P = 0.016) and grade 3/4 diarrhea rates (1.3% vs 14.2% P < 0.001). No statistically significant differences in surgical complication rates were seen (SC 53.2 vs 50.4% LC, p = 0.68), although permanent stoma (38.0% vs 29.8%, P = 0.13) and anastomotic breakdown (7.1% vs 3.5%, P = 0.26) rates favored LC with perineal wound complications (38.3% vs 50.0%, P = 0.26) in favor of SC. CONCLUSIONS:LC had significantly higher AEs compared with SC with no statistically significant differences in postoperative complications. There were clinical trends in permanent stoma rates and anastomotic leaks in favor of LC but with an increased perineal wound breakdown rate.
Authors: Wang Qiaoli; Huang Yongping; Xiong Wei; Xu Guoqiang; Ju Yunhe; Liu Qiuyan; Li Cheng; Guo Mengling; Li Jiayi; Xiong Wei; Yang Yi Journal: Int J Colorectal Dis Date: 2019-11-19 Impact factor: 2.571
Authors: Santiago Avila; George J Chang; N Arvind Dasari; Danyal A Smani; Prajnan Das; Joeseph M Herman; Eugene Koay; Albert Koong; Sunil Krishnan; Bruce D Minsky; Grace L Smith; Cullen Taniguchi; Melissa W Taggart; Harmeet Kaur; Emma B Holliday Journal: Clin Colorectal Cancer Date: 2020-02-08 Impact factor: 4.481
Authors: Jun Seok Park; Min Kyu Kang; Seung Ho Song; Gyu-Seog Choi; Soo Yeun Park; Hye Jin Kim; Jong Gwang Kim; Byung Woog Kang; Jin Ho Baek; Dong Won Baek; Jae-Chul Kim; Shin-Hyung Park; Seung Hyun Cho; An Na Seo Journal: Int J Colorectal Dis Date: 2021-02-06 Impact factor: 2.571
Authors: Hans Geinitz; Carsten Nieder; Lukas Kocik; Christine Track; Johann Feichtinger; Theresa Weingartner; Kurt Spiegl; Barbara Füreder-Kitzmüller; Johanna Kaufmann; Dietmar H Seewald; Reinhold Függer; Andreas Shamiyeh; Andreas L Petzer; David Kiesl; Josef Hammer Journal: Radiat Oncol Date: 2020-05-14 Impact factor: 3.481
Authors: Séan M O'Cathail; Steven Davis; Jane Holmes; Richard Brown; Kerry Fisher; Leonard Seymour; Richard Adams; James Good; David Sebag-Montefiore; Tim Maughan; Maria A Hawkins Journal: Radiat Oncol Date: 2020-06-12 Impact factor: 3.481